Capabilities
The women’s health market is predicted to be among the fastest growing investment areas within the healthcare and life sciences industry. Life sciences companies and healthcare providers, as well as the governmental bodies that regulate them, are abandoning a “one-size-fits-all” approach to treatment in favor of approaches more tailored to specific groups, including women. King & Spalding’s Women’s Health team has decades of experience advising companies in this space on issues that arise throughout the lifecycle of medical products – including intellectual property issues, corporate and M&A issues, FDA-related issues, issues related to product coverage and reimbursement, healthcare provider issues, and product liability issues. Clients include drug and device manufacturers, health care providers, private equity firms, and others.
December 28, 2020
California Medicaid Set to Lose $200 Million in Funding Next Quarter for its Universal Abortion Coverage Mandate
October 6, 2020
FDA Announces Updates to Two Guidance Documents Concerning Breast Implant Safety and Transparency
September 1, 2020
FDA Continues its Focus on Breast Implant Safety and Transparency with an Eye Toward Improving Regulatory Decision-Making
January 26, 2021
Top Healthcare Partner Richard Zall Joins King & Spalding in New York
February 5, 2020
Morty Dubin counsels Johnson & Johnson with its talc trial in New Jersey
January 23, 2020
Paul Johnson and Julia Romano counsel Johnson & Johnson before a California appeals panel, which upheld a favorable verdict for the company
April 5, 2019
King & Spalding Team Achieves Defense Verdict in Johnson & Johnson Talcum Powder Trial
February 19, 2019
Johnson & Johnson Wins Full Dismissal on the Eve of Trial